Drug Dev
Crescendo aims to increase IO share of voice with Humabody platform
The Immuno-oncology space is a crowded and consequently represents a big challenge for small biotechs to get share of voice. Crescendo Biologics CEO Peter Pack took time off from his busy partnering schedule at BIO-Europe Spring 2018 to outline to Scrip how the company's Humabody platform is being used to develop both in-house and partnered opportunities.